Cargando…

Risikoidentifikation bei Polypharmazie in einer Pflegeheimpopulation

INTRODUCTION: Multimorbidity in old age is one reason for intensified pharmacotherapy. At the same time, an increase in medications could augment multimorbidity, especially when drug interactions leading to undesired drug effects occur. METHODS: In this cross-sectional study 918 mentally ill seniors...

Descripción completa

Detalles Bibliográficos
Autores principales: Specka, Michael, Groll, Maria, Scherbaum, Norbert, Wiltfang, Jens, Benninghoff, Jens
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Medizin 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9064868/
https://www.ncbi.nlm.nih.gov/pubmed/33570659
http://dx.doi.org/10.1007/s00391-021-01850-6
_version_ 1784699477817294848
author Specka, Michael
Groll, Maria
Scherbaum, Norbert
Wiltfang, Jens
Benninghoff, Jens
author_facet Specka, Michael
Groll, Maria
Scherbaum, Norbert
Wiltfang, Jens
Benninghoff, Jens
author_sort Specka, Michael
collection PubMed
description INTRODUCTION: Multimorbidity in old age is one reason for intensified pharmacotherapy. At the same time, an increase in medications could augment multimorbidity, especially when drug interactions leading to undesired drug effects occur. METHODS: In this cross-sectional study 918 mentally ill seniors living in nursing homes (mean age 79.3 (±11.6) years; 31.8% male) were included. Two different approaches to assess risks due to pharmacotherapy were applied: first mediQ, an online-based clinical decision support software (CDSS) and the PRISCUS list, which indicates potentially inappropriate medication. PRISCUS is the German equivalent to the American Geriatrics Society Beers criteria. RESULTS: Of the patients in the study 76.3% were at clinical risk, 2.2% at potentially high risk for drug interactions regarding the entire medication as tested by mediQ, and about 25% of the studied population received potentially inappropriate medication according to the PRISCUS list. CONCLUSION: This difference clearly underlines the cumbersome complexity of identifying patients at risk by using these exemplary devices. The focus of avoiding undesired drug side effects should be taking medication only after thorough verification of clinical indications and under close monitoring. The CDSS or negative lists may support this process.
format Online
Article
Text
id pubmed-9064868
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Medizin
record_format MEDLINE/PubMed
spelling pubmed-90648682022-05-07 Risikoidentifikation bei Polypharmazie in einer Pflegeheimpopulation Specka, Michael Groll, Maria Scherbaum, Norbert Wiltfang, Jens Benninghoff, Jens Z Gerontol Geriatr Originalien INTRODUCTION: Multimorbidity in old age is one reason for intensified pharmacotherapy. At the same time, an increase in medications could augment multimorbidity, especially when drug interactions leading to undesired drug effects occur. METHODS: In this cross-sectional study 918 mentally ill seniors living in nursing homes (mean age 79.3 (±11.6) years; 31.8% male) were included. Two different approaches to assess risks due to pharmacotherapy were applied: first mediQ, an online-based clinical decision support software (CDSS) and the PRISCUS list, which indicates potentially inappropriate medication. PRISCUS is the German equivalent to the American Geriatrics Society Beers criteria. RESULTS: Of the patients in the study 76.3% were at clinical risk, 2.2% at potentially high risk for drug interactions regarding the entire medication as tested by mediQ, and about 25% of the studied population received potentially inappropriate medication according to the PRISCUS list. CONCLUSION: This difference clearly underlines the cumbersome complexity of identifying patients at risk by using these exemplary devices. The focus of avoiding undesired drug side effects should be taking medication only after thorough verification of clinical indications and under close monitoring. The CDSS or negative lists may support this process. Springer Medizin 2021-02-11 2022 /pmc/articles/PMC9064868/ /pubmed/33570659 http://dx.doi.org/10.1007/s00391-021-01850-6 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access Dieser Artikel wird unter der Creative Commons Namensnennung 4.0 International Lizenz veröffentlicht, welche die Nutzung, Vervielfältigung, Bearbeitung, Verbreitung und Wiedergabe in jeglichem Medium und Format erlaubt, sofern Sie den/die ursprünglichen Autor(en) und die Quelle ordnungsgemäß nennen, einen Link zur Creative Commons Lizenz beifügen und angeben, ob Änderungen vorgenommen wurden. Die in diesem Artikel enthaltenen Bilder und sonstiges Drittmaterial unterliegen ebenfalls der genannten Creative Commons Lizenz, sofern sich aus der Abbildungslegende nichts anderes ergibt. Sofern das betreffende Material nicht unter der genannten Creative Commons Lizenz steht und die betreffende Handlung nicht nach gesetzlichen Vorschriften erlaubt ist, ist für die oben aufgeführten Weiterverwendungen des Materials die Einwilligung des jeweiligen Rechteinhabers einzuholen. Weitere Details zur Lizenz entnehmen Sie bitte der Lizenzinformation auf http://creativecommons.org/licenses/by/4.0/deed.de (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Originalien
Specka, Michael
Groll, Maria
Scherbaum, Norbert
Wiltfang, Jens
Benninghoff, Jens
Risikoidentifikation bei Polypharmazie in einer Pflegeheimpopulation
title Risikoidentifikation bei Polypharmazie in einer Pflegeheimpopulation
title_full Risikoidentifikation bei Polypharmazie in einer Pflegeheimpopulation
title_fullStr Risikoidentifikation bei Polypharmazie in einer Pflegeheimpopulation
title_full_unstemmed Risikoidentifikation bei Polypharmazie in einer Pflegeheimpopulation
title_short Risikoidentifikation bei Polypharmazie in einer Pflegeheimpopulation
title_sort risikoidentifikation bei polypharmazie in einer pflegeheimpopulation
topic Originalien
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9064868/
https://www.ncbi.nlm.nih.gov/pubmed/33570659
http://dx.doi.org/10.1007/s00391-021-01850-6
work_keys_str_mv AT speckamichael risikoidentifikationbeipolypharmazieineinerpflegeheimpopulation
AT grollmaria risikoidentifikationbeipolypharmazieineinerpflegeheimpopulation
AT scherbaumnorbert risikoidentifikationbeipolypharmazieineinerpflegeheimpopulation
AT wiltfangjens risikoidentifikationbeipolypharmazieineinerpflegeheimpopulation
AT benninghoffjens risikoidentifikationbeipolypharmazieineinerpflegeheimpopulation